RGBP News and Press, Regen BioPharma Inc From 12/19/22

Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer PR Newswire SAN DIEGO , Dec. 19, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) As 2022 comes to a close, I would like to hig...

Regen BioPharma Appoints Two New Scientific Advisory Board Members PR Newswire Company is Bolstering its Scientific Board in the Area of Immunotherapy SAN DIEGO , Dec. 7, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) an...

Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic PR Newswire Initial Design and Testing Complete SAN DIEGO , Nov. 18, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has previously discussed initiation...

Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic PR Newswire DuraCAR Drug Addresses Major Need in Solid Tumor Therapies SAN DIEGO , Nov. 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)ha...

Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space PR Newswire Understanding CAR-T Mechanism of Action SAN DIEGO , Oct. 26, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) has filed several patent...

Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy PR Newswire Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach SAN DIEGO , Se...

Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy PR Newswire Company Engages Top-Tier Contract Research Organization SAN DIEGO , Sept. 13, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC P...

Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors PR Newswire Company Develops A Two-Step Sequential Approach SAN DIEGO , Aug. 25, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PIN...

Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors PR Newswire Company Creates "Younger T Cells" for Fighting Cancer Using its NR2F6 Technology SAN DIEGO , Aug. 11, 2022 /PR...

The shares of nanocap biotech Regen BioPharma ( OTCPK:RGBP ) surged 21% on Wednesday to reach the highest level since May after the company announced the submission of a U.S. patent application related to a mRNA cancer immunotherapeutic vaccine. The provisional patent appl...